deltatrials

Ovarian cancer Trials in Goyang-si, South Korea

Conditions / Ovarian cancer / Goyang-si, South Korea

Clinical trials for Ovarian cancer investigate a range of treatment strategies and patient populations.

10 total trials for this combination

Trials

NCT ID Title Status Phase
NCT02580058 A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) COMPLETED PHASE3
NCT05827523 Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04) RECRUITING PHASE3
NCT06824467 A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) RECRUITING
NCT01538498 Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer COMPLETED
NCT05445778 Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer RECRUITING PHASE3
NCT07171528 Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer RECRUITING PHASE2
NCT03038100 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer COMPLETED PHASE3
NCT02718417 Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) TERMINATED PHASE3
NCT06819007 Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) RECRUITING PHASE3
NCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing ACTIVE_NOT_RECRUITING

Related Pages